Cover Image
QR Code

Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Nonalcoholic fatty liver disease (NAFLD) affects 75 to 100 million adults in the United States and is the leading cause of chronic liver disease worldwide, fueled by the rising epidemic of obesity and metabolic syndrome. NAFLD is the hepatic manifestation of metabolic syndrome; thus, accurately asse...

Full description

Published in:Gastroenterology & Hepatology Vol. 15; no. 2; pp. 83 - 90
Main Authors: Wong, Terrence, Wong, Robert J., Gish, Robert G.
Format: tables/charts Journal Article
Published: Gastro-Hep Communications, Inc Feb2019
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134881514&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 134881514
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15547914
        6N5B
      jtl: Gastroenterology & Hepatology
      issn: 15547914
      maglogo: N
    pubinfo:
      dt: Feb2019
      vid: 15
      iid: 2
      pid: 72163
      pub: Gastro-Hep Communications, Inc
      place: New York, New York
    artinfo:
      ui:
        134881514
        134881514
        134881514
        134881514
      ppf: 83
      ppct: 7
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
      aug:
        au:
          Wong, Terrence
          Wong, Robert J.
          Gish, Robert G.
        affil: Resident physician in the Department of Medicine in the Division of Gastroenterology and Hepatology at Alameda Health System-Highland Hospital in Oakland, California
      sug:
        subj:
          Nonalcoholic Fatty Liver Disease Diagnosis
          Nonalcoholic Fatty Liver Disease Therapy
          Metabolic Syndrome X Symptoms
          Comorbidity
          Disease Progression
          Liver Cirrhosis Risk Factors
          Nonalcoholic Fatty Liver Disease Complications
          Nonalcoholic Fatty Liver Disease Prognosis
          Severity of Illness
          Cost Benefit Analysis
      ab: Nonalcoholic fatty liver disease (NAFLD) affects 75 to 100 million adults in the United States and is the leading cause of chronic liver disease worldwide, fueled by the rising epidemic of obesity and metabolic syndrome. NAFLD is the hepatic manifestation of metabolic syndrome; thus, accurately assessing and managing comorbid metabolic syndrome components is paramount. Nonalcoholic steatohepatitis (NASH) is a subset of NAFLD that includes a more progressive and advanced form of the disease, with a greater risk of fibrosis progression. Correctly diagnosing and staging NAFLD and distinguishing the subset of NASH patients is not only critical for disease monitoring and prognostication, but also holds potential implications for therapies. Although the current therapeutic landscape for NAFLD does not offer many options, future therapies are on the horizon. Properly staging the severity of disease and fibrosis is especially important when considering the eligibility and cost-effectiveness of these therapies.
      pubtype: Academic Journal
      doctype:
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N